Temat: "Programmed Cell Death 1 Receptor" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Rab37 mediates trafficking and membrane presentation of PD-1 to sustain T cell exhaustion in lung cancer.
Autorzy:: Kuo WT; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.
Kuo IY; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.; Department of Biotechnology, College of Biomedical Science, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hsieh HC; Institute of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wu ST; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan.
Su WC; Division of Oncology, Department of Internal Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Wang YC; Department of Pharmacology, College of Medicine, National Cheng Kung University, No. 1, University Road, Tainan, 701, Taiwan. .; Institute of Basic Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. .; Pokaż więcej
Źródło:: Journal of biomedical science [J Biomed Sci] 2024 Feb 07; Vol. 31 (1), pp. 20. Date of Electronic Publication: 2024 Feb 07.
Typ publikacji:: Journal Article
MeSH Terms:: Lung Neoplasms*/pathology
Monomeric GTP-Binding Proteins*/metabolism
Animals ; Humans ; Mice ; CD8-Positive T-Lymphocytes/metabolism ; Hepatitis A Virus Cellular Receptor 2/metabolism ; Leukocytes, Mononuclear/metabolism ; Mice, Knockout ; Programmed Cell Death 1 Receptor ; rab GTP-Binding Proteins ; T-Cell Exhaustion ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non-small-cell lung cancer.
Autorzy:: Liu L; The Second Affiliated Hospital of Soochow University, Suzhou, China.; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Zhang S; Zhu Zhou Central Hospital, Zhuzhou, 412007, China.
Yang HY; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Zhou CH; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Xiong Y; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China.
Yang N; Department of Medical Oncology, Lung Cancer and Gastrointestinal Unit, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, China. .
Tian Y; The Second Affiliated Hospital of Soochow University, Suzhou, China. .; Pokaż więcej
Źródło:: Lipids in health and disease [Lipids Health Dis] 2024 Jan 13; Vol. 23 (1), pp. 16. Date of Electronic Publication: 2024 Jan 13.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Indoles*
Quinolines*
Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor/genetics ; Programmed Cell Death 1 Receptor/metabolism ; Programmed Cell Death 1 Receptor/therapeutic use ; Lipids/therapeutic use

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Autorzy:: Liu JS; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
Cai YX; Department of Pathology, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
He YZ; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
Xu J; Department of Pathology, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China.
Tian SF; Department of Pathology, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China. .
Li ZQ; Department of Neurosurgery, Zhongnan Hospital of Wuhan University, 430062, Wuhan, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 24; Vol. 24 (1), pp. 123. Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Brain Neoplasms*
Adenocarcinoma of Lung*
Humans ; B7-H1 Antigen ; CTLA-4 Antigen ; Programmed Cell Death 1 Receptor ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Gut microbiome for predicting immune checkpoint blockade-associated adverse events.
Autorzy:: Hu M; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Lin X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Sun T; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Shao X; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China.
Huang X; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Du W; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China.
Guo M; Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, China.
Zhu X; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Zhou Y; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Tong T; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China.
Guo F; Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, 310003, China.
Han T; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Wu X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China.
Shi Y; Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Shanghai Jiao Tong University, 1954 Huashan Road, Shanghai, 200030, China.
Xiao X; Department of Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. .
Zhang Y; Department of Medical Oncology, Xuzhou Central Hospital, Clinical School of Xuzhou Medical University, Xuzhou, 221009, China. .
Hong J; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China. .
Chen H; State Key Laboratory of Systems Medicine for Cancer, NHC Key Laboratory of Digestive Diseases, Division of Gastroenterology and Hepatology, School of Medicine, Renji Hospital, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai Cancer Institute, Shanghai, 200001, China. .; Pokaż więcej
Źródło:: Genome medicine [Genome Med] 2024 Jan 19; Vol. 16 (1), pp. 16. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji:: Journal Article
MeSH Terms:: Neoplasms*/drug therapy
Gastrointestinal Microbiome*
Antineoplastic Agents, Immunological*/therapeutic use
Drug-Related Side Effects and Adverse Reactions*
Immune System Diseases*
Lung Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; RNA, Ribosomal, 16S/genetics ; Vitamin K 2/therapeutic use ; Immunotherapy/adverse effects ; Programmed Cell Death 1 Receptor ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.
Autorzy:: Li R; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Liang H; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Li J; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China.
Shao Z; Department of Radiation Oncology, Qilu Hospital of Shandong University, 250012, Jinan, China.
Yang D; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Bao J; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Wang K; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Xi W; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Gao Z; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Guo R; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China.
Mu X; Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 18; Vol. 24 (1), pp. 107. Date of Electronic Publication: 2024 Jan 18.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Adenocarcinoma*/drug therapy
Carcinoma, Squamous Cell*/drug therapy
Humans ; Paclitaxel ; Liposomes ; Immune Checkpoint Inhibitors/adverse effects ; Programmed Cell Death 1 Receptor/therapeutic use ; Retrospective Studies ; Immunotherapy/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Autorzy:: Qin B; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China.
Xin L; Department of Gynaecology and Obstetrics, PLA Rocket Force Characteristic Medical Center, Xinjiekou outer Street 16, Xicheng district, 100088, Beijing, China.; Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Liang C; Medical Service Department, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Li L; Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Song Q; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China.
Long Y; Department of Graduate Administration, PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Zhang X; Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Wang D; Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Shi W; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China.
Zhang J; Department of Oncology, The First Medical Center of PLA General Hospital, Fuxing Road 28, Haidian district, 100853, Beijing, China.
Hu Y; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. .
Yang B; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. .
Xiong Q; Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, 4th West Ring Road 100, Fengtai district, 100039, Beijing, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2024 Jan 17; Vol. 24 (1), pp. 100. Date of Electronic Publication: 2024 Jan 17.
Typ publikacji:: Multicenter Study; Journal Article
MeSH Terms:: Lung Neoplasms*/drug therapy
Small Cell Lung Carcinoma*/drug therapy
Humans ; B7-H1 Antigen ; Immune Checkpoint Inhibitors/adverse effects ; Programmed Cell Death 1 Receptor ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Spatial features of specific CD103 tissue-resident memory T cell subsets define the prognosis in patients with non-small cell lung cancer.
Autorzy:: Yang G; Shandong University Cancer Center, Shandong University, Jinan, Shandong, China.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Cai S; Shandong University Cancer Center, Shandong University, Jinan, Shandong, China.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Hu M; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.; Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Li C; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.; School of Clinical Medicine, Weifang Medical University, Weifang, Shandong, China.
Yang L; Shandong University Cancer Center, Shandong University, Jinan, Shandong, China.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Zhang W; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Sun J; Department of Pathology, Shandong Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China.
Sun F; Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Xing L; Shandong University Cancer Center, Shandong University, Jinan, Shandong, China.; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China.
Sun X; Shandong University Cancer Center, Shandong University, Jinan, Shandong, China. .; Department of Nuclear Medicine, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China. .; Pokaż więcej
Źródło:: Journal of translational medicine [J Transl Med] 2024 Jan 05; Vol. 22 (1), pp. 27. Date of Electronic Publication: 2024 Jan 05.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*
Lung Neoplasms*
Humans ; Hepatitis A Virus Cellular Receptor 2 ; Memory T Cells ; Programmed Cell Death 1 Receptor ; Prognosis ; CD8-Positive T-Lymphocytes ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: LAG3 is an independent prognostic biomarker and potential target for immune checkpoint inhibitors in malignant pleural mesothelioma: a retrospective study.
Autorzy:: Arimura K; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan. .
Hiroshima K; Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.
Nagashima Y; Department of Surgical Pathology, Tokyo Women's Medical University, Tokyo, Japan.
Nakazawa T; Department of Pathology, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.
Ogihara A; Department of Thoracic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Orimo M; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Sato Y; Graduate School of Public Health, Shizuoka Graduate University of Public Health, Shizuoka, Japan.
Katsura H; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Kanzaki M; Department of Thoracic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Kondo M; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.
Tagaya E; Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2023 Dec 07; Vol. 23 (1), pp. 1206. Date of Electronic Publication: 2023 Dec 07.
Typ publikacji:: Journal Article
MeSH Terms:: Mesothelioma, Malignant*
Mesothelioma*/drug therapy
Mesothelioma*/genetics
Mesothelioma*/metabolism
Pleural Neoplasms*/drug therapy
Pleural Neoplasms*/genetics
Pleural Neoplasms*/metabolism
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/metabolism
Humans ; Female ; Retrospective Studies ; Immune Checkpoint Inhibitors ; Prognosis ; Programmed Cell Death 1 Receptor ; RNA, Messenger/genetics ; Biomarkers, Tumor/analysis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Autorzy:: Wang Y; Department of Medical Oncology, The First Medical Center, Chinese PLA General Hospital, Beijing, China.; Chinese PLA Medical School, Beijing, China.
Li L; School of Medicine, Nankai University, Tianjin, China.
Hu J; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.; Department of Medical Oncology, The Seventh Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhao Y; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Yan H; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Gao M; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Yang X; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhang X; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. .
Ma J; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. .
Dai G; Department of Medical Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2023 Dec 06; Vol. 23 (1), pp. 1196. Date of Electronic Publication: 2023 Dec 06.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study
MeSH Terms:: Lung Neoplasms*/drug therapy
Small Cell Lung Carcinoma*/drug therapy
Humans ; B7-H1 Antigen ; Etoposide ; Immune Checkpoint Inhibitors/adverse effects ; Platinum/pharmacology ; Platinum/therapeutic use ; Programmed Cell Death 1 Receptor ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Autorzy:: Su S; The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Chen F; The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Xu M; The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Liu B; The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.
Wang L; The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Dec; Vol. 14 (34), pp. 3361-3368. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/therapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/therapy
Lung Neoplasms*/drug therapy
Cancer Vaccines*/therapeutic use
Humans ; Programmed Cell Death 1 Receptor ; Immune Checkpoint Inhibitors/therapeutic use ; Antigens, Neoplasm/genetics ; Antigens, Neoplasm/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: TIM-3 expression induces resistance to PD-1 inhibitor in G-CSF-producing lung spindle cell carcinoma: A case report.
Autorzy:: Hayashi F; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
Akagi K; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
Taniguchi H; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.
Matsutake T; Department of Respiratory Medicine, Kouseikai Hospital, Nagasaki, Japan.
Kawahara H; Department of Internal Medicine, Kouseikai Hospital, Nagasaki, Japan.
Sekine I; Department of Pathology, Kouseikai Hospital, Nagasaki, Japan.
Gyotoku H; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Takemoto S; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Soda H; Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo, Japan.
Ashizawa K; Clinical Oncology Center, Nagasaki University Hospital, Nagasaki, Japan.; Department of Clinical Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Mukae H; Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.; Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Dec; Vol. 14 (36), pp. 3556-3560. Date of Electronic Publication: 2023 Nov 05.
Typ publikacji:: Case Reports
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/pathology
Carcinoma*
Male ; Humans ; Aged, 80 and over ; Immune Checkpoint Inhibitors/therapeutic use ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Hepatitis A Virus Cellular Receptor 2/therapeutic use ; CD8-Positive T-Lymphocytes/metabolism ; Programmed Cell Death 1 Receptor/metabolism ; Lung/pathology ; B7-H1 Antigen/metabolism ; Tumor Microenvironment

Raport

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials.
Autorzy:: de Moraes FCA; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto, Rua dos Mundurucus, nº4487, Belém, 66073-000, PA, Brazil. .
Pasqualotto E; Federal University of Santa Catarina, Florianópolis, 88040-900, Santa Catarina, Brazil.
Lopes LM; Sciences Medical School of Santos, Santos, São Paulo, 11045-101, Brazil.
Cavalcanti Souza ME; University of Pernambuco, Recife, 50670-901, Pernambuco, Brazil.
de Oliveira Rodrigues ALS; University Center of João Pessoa, João Pessoa, Paraíba, 58053-000, Brazil.
de Almeida AM; Federal University of Mato Grosso, Sinop, 78550-704, Mato Grosso, Brazil.
Stecca C; Mackenzie Evangelical University Hospital, Curitiba, 80730-150, Paraná, Brazil.
Fernandes MR; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto, Rua dos Mundurucus, nº4487, Belém, 66073-000, PA, Brazil.
Dos Santos NPC; Oncology Research Center, Federal University of Pará, University Hospital João de Barros de Barreto, Rua dos Mundurucus, nº4487, Belém, 66073-000, PA, Brazil.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2023 Nov 29; Vol. 23 (1), pp. 1166. Date of Electronic Publication: 2023 Nov 29.
Typ publikacji:: Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:: Endometrial Neoplasms*/drug therapy
Lung Neoplasms*/drug therapy
Female ; Humans ; Carboplatin ; Paclitaxel ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor/therapeutic use ; Randomized Controlled Trials as Topic ; B7-H1 Antigen

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis.
Autorzy:: Karampitsakos T; Department of Respiratory Medicine, University Hospital of Patras, Rio, Greece.; Ubben Center and Laboratory for Pulmonary Fibrosis Research, Morsani College of Medicine, University of South Florida, 33620, Tampa, FL, USA.
Galaris A; Institute of Bio- Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
Chrysikos S; 5th Department of Pneumonology, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.
Papaioannou O; Department of Respiratory Medicine, University Hospital of Patras, Rio, Greece.
Vamvakaris I; Department of Pathology, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.
Barbayianni I; Institute of Bio- Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
Kanellopoulou P; Institute of Bio- Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
Grammenoudi S; Institute of Bio- Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
Anagnostopoulos N; First Academic Department of Pneumonology, 'SOTIRIA', Medical School, Hospital for Thoracic Diseases, National and Kapodistrian University of Athens, Athens, Greece.
Stratakos G; First Academic Department of Pneumonology, 'SOTIRIA', Medical School, Hospital for Thoracic Diseases, National and Kapodistrian University of Athens, Athens, Greece.
Katsaras M; Department of Respiratory Medicine, University Hospital of Patras, Rio, Greece.
Sampsonas F; Department of Respiratory Medicine, University Hospital of Patras, Rio, Greece.
Dimakou K; 5th Department of Pneumonology, Hospital for Thoracic Diseases, 'SOTIRIA', Athens, Greece.
Manali ED; 2nd Pulmonary Medicine Department, Athens Medical School, 'ATTIKON' University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papiris S; 2nd Pulmonary Medicine Department, Athens Medical School, 'ATTIKON' University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Tourki B; Ubben Center and Laboratory for Pulmonary Fibrosis Research, Morsani College of Medicine, University of South Florida, 33620, Tampa, FL, USA.
Juan-Guardela BM; Ubben Center and Laboratory for Pulmonary Fibrosis Research, Morsani College of Medicine, University of South Florida, 33620, Tampa, FL, USA.
Bakakos P; First Academic Department of Pneumonology, 'SOTIRIA', Medical School, Hospital for Thoracic Diseases, National and Kapodistrian University of Athens, Athens, Greece.
Bouros D; First Academic Department of Pneumonology, 'SOTIRIA', Medical School, Hospital for Thoracic Diseases, National and Kapodistrian University of Athens, Athens, Greece.
Herazo-Maya JD; Ubben Center and Laboratory for Pulmonary Fibrosis Research, Morsani College of Medicine, University of South Florida, 33620, Tampa, FL, USA.
Aidinis V; Institute of Bio- Innovation, Biomedical Sciences Research Center Alexander Fleming, Athens, Greece.
Tzouvelekis A; Department of Respiratory Medicine, University Hospital of Patras, Rio, Greece. .; Pokaż więcej
Źródło:: Respiratory research [Respir Res] 2023 Nov 14; Vol. 24 (1), pp. 279. Date of Electronic Publication: 2023 Nov 14.
Typ publikacji:: Journal Article
MeSH Terms:: Idiopathic Pulmonary Fibrosis*/chemically induced
Idiopathic Pulmonary Fibrosis*/drug therapy
Idiopathic Pulmonary Fibrosis*/metabolism
Lung Neoplasms*/metabolism
Humans ; Mice ; Animals ; Programmed Cell Death 1 Receptor/genetics ; B7-H1 Antigen/genetics ; B7-H1 Antigen/metabolism ; Lung/metabolism ; Bleomycin/toxicity ; Lymph Nodes/pathology ; RNA, Messenger/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Survival and biomarkers for cachexia in non-small cell lung cancer receiving immune checkpoint inhibitors.
Autorzy:: Murata D; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Azuma K; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Matsuo N; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Murotani K; Biostatistics Center, Kurume University School of Medicine, Fukuoka, Japan.
Matama G; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Kawahara A; Department of Diagnostic Pathology, Kurume University Hospital, Fukuoka, Japan.
Sasada T; Cancer Vaccine and Immunotherapy Center and Division of Cancer Immunotherapy, Kanagawa Cancer Center Research Institute, Kanagawa, Japan.
Tokito T; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.
Hoshino T; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Fukuoka, Japan.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2023 Oct; Vol. 12 (19), pp. 19471-19479. Date of Electronic Publication: 2023 Sep 15.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/complications
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/complications
Lung Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Ghrelin/therapeutic use ; Cachexia/etiology ; Programmed Cell Death 1 Receptor ; Retrospective Studies ; Biomarkers, Tumor/analysis ; Neoplasm Recurrence, Local ; Prognosis ; B7-H1 Antigen/analysis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: High endothelial venules predict response to PD-1 inhibitors combined with anti-angiogenesis therapy in NSCLC.
Autorzy:: Ye D; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Jin Y; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Weng Y; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Cui X; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Wang J; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China.
Peng M; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China. .
Song Q; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China. .; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2023 Sep 30; Vol. 13 (1), pp. 16468. Date of Electronic Publication: 2023 Sep 30.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/pathology
Humans ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/metabolism ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Programmed Cell Death 1 Receptor ; Retrospective Studies ; Venules/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Characterization of TCF-1 and its relationship between CD8+ TIL densities and immune checkpoints and their joint influences on prognoses of lung adenocarcinoma patients.
Autorzy:: Jiang K; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Liu S; Department of Rehabilitation Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Chen Y; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xu Z; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xu Z; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Qian B; Gerontology Department, Huadong Sanatorium, Wuxi, China.
Ding Q; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Cui H; Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Sui Y; Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Cao D; Department of Rehabilitation Medicine, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Xu W; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.
Shen M; Department of Thoracic and Cardiac Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, China.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Sep; Vol. 14 (27), pp. 2745-2753. Date of Electronic Publication: 2023 Aug 03.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adenocarcinoma*
Adenocarcinoma of Lung*
Lung Neoplasms*/pathology
Humans ; B7-H1 Antigen/metabolism ; CD8-Positive T-Lymphocytes/metabolism ; Hepatitis A Virus Cellular Receptor 2 ; Prognosis ; Programmed Cell Death 1 Receptor/metabolism ; Tumor Microenvironment

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis.
Autorzy:: Nelli F; Thoracic Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Virtuoso A; Thoracic Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Giannarelli D; Biostatistics Unit, Scientific Directorate, Fondazione Policlinico Universitario A. Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 00168 Rome, Italy.
Fabbri A; Medical Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Giron Berrios JR; Medical Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Marrucci E; Medical Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Fiore C; Medical Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.
Ruggeri EM; Medical Oncology Unit, Department of Oncology and Hematology, Central Hospital of Belcolle, 01100 Viterbo, Italy.; Pokaż więcej
Źródło:: Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Sep 01; Vol. 30 (9), pp. 8117-8133. Date of Electronic Publication: 2023 Sep 01.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Immune Checkpoint Inhibitors ; Acetaminophen ; B7-H1 Antigen ; Programmed Cell Death 1 Receptor ; Propensity Score

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Biomarkers for Immune Checkpoint Inhibitor Response in NSCLC: Current Developments and Applicability.
Autorzy:: Tostes K; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.
Siqueira AP; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.
Reis RM; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.; Life and Health Sciences Research Institute (ICVS), Medical School, University of Minho, 4710-057 Braga, Portugal.; ICVS/3B's-PT Government Associate Laboratory, 4806-909 Guimarães, Portugal.
Leal LF; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.; Barretos School of Health Sciences, Dr. Paulo Prata-FACISB, Barretos 14785-002, São Paulo, Brazil.
Arantes LMRB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos 14784-400, São Paulo, Brazil.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Jul 25; Vol. 24 (15). Date of Electronic Publication: 2023 Jul 25.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/metabolism
Lung Neoplasms*/metabolism
Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Programmed Cell Death 1 Receptor ; Biomarkers ; Immunotherapy/methods ; B7-H1 Antigen ; Biomarkers, Tumor/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Comprehensive Review: Unveiling the Pro-Oncogenic Roles of IL-1ß and PD-1/PD-L1 in NSCLC Development and Targeting Their Pathways for Clinical Management.
Autorzy:: Castillo DR; Division of Hematology and Oncology, Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.
Jeon WJ; Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Park D; Department of Internal Medicine, University of San Francisco-Fresno, Fresno, CA 93701, USA.
Pham B; Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Yang C; Department of Internal Medicine, School of Medicine, University of California Riverside, Riverside, CA 92521, USA.
Joung B; Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Moon JH; Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Lee J; School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Chong EG; Division of Hematology and Oncology, Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.
Park K; Department of Pharmacy, Loma Linda University, Loma Linda, CA 92350, USA.
Reeves ME; Division of Hematology and Oncology, Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.
Duerksen-Hughes P; Division of Biochemistry, Department of Medicine & Basic Sciences, School of Medicine, Loma Linda University, Loma Linda, CA 92350, USA.
Mirshahidi HR; Division of Hematology and Oncology, Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.
Mirshahidi S; Biospecimen Laboratory, Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.; Division of Microbiology and Molecular Genetics, Department of Medicine & Basic Sciences, Loma Linda University, Loma Linda 92350, CA, USA.; Pokaż więcej
Źródło:: International journal of molecular sciences [Int J Mol Sci] 2023 Jul 17; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 17.
Typ publikacji:: Journal Article; Review; Systematic Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Non-Small-Cell Lung*/genetics
Carcinoma, Non-Small-Cell Lung*/pathology
Lung Neoplasms*/drug therapy
Lung Neoplasms*/genetics
Lung Neoplasms*/pathology
Humans ; B7-H1 Antigen/genetics ; Immunotherapy ; Programmed Cell Death 1 Receptor/genetics ; Tumor Microenvironment/genetics ; Interleukin-1beta

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy.
Autorzy:: Liu S; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Wang H; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.; Qingdao University of Science and Technology, Qingdao, 266042, People's Republic of China.
Shao X; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Chen H; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Chao S; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Zhang Y; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Gao Z; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Yao Q; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China.
Zhang P; School of Pharmaceutical Sciences & Institute of Materia Medica, Shandong First Medical University & Shandong Academy of Medical Sciences, National Key Laboratory of Advanced Drug Delivery System, Key Laboratory for Biotechnology Drugs of National Health Commission (Shandong Academy of Medical Sciences), Key Lab for Rare & Uncommon Diseases of Shandong Province, Jinan, 250117, Shandong, China. .; Pokaż więcej
Źródło:: Journal of nanobiotechnology [J Nanobiotechnology] 2023 Jul 04; Vol. 21 (1), pp. 207. Date of Electronic Publication: 2023 Jul 04.
Typ publikacji:: Journal Article; Review
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Melanoma*/drug therapy
Humans ; Programmed Cell Death 1 Receptor ; Immune Checkpoint Inhibitors ; Immunotherapy/methods

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Programmed Cell Death 1 Receptor"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język